Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma

The Key Non- Tuberculous Mycobacterial Infections Companies in the market include - Insmed, AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others.
The Non- Tuberculous Mycobacterial Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non- Tuberculous Mycobacterial Infections pipeline products will significantly revolutionize the Non- Tuberculous Mycobacterial Infections market dynamics.

DelveInsight's "Non- Tuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Non- Tuberculous Mycobacterial Infections, historical and forecasted epidemiology as well as the Non- Tuberculous Mycobacterial Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Non- Tuberculous Mycobacterial Infections market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Non- Tuberculous Mycobacterial Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non- Tuberculous Mycobacterial Infections Market Forecast [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Non- Tuberculous Mycobacterial Infections Market Report:

*
The Non- Tuberculous Mycobacterial Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In December 2024, Shanghai MicuRx Pharmaceutical (688373.SH) announced that its anti-infection drug, MRX-5, has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of non-tuberculous mycobacteria (NTM) infections, representing a significant milestone in NTM treatment.

*
In October 2024, Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, announced the publication of data from its Phase 1 clinical trial. The study evaluated the intrapulmonary pharmacokinetics (PK) of SPR719. The full manuscript, titled "Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers," was published ahead of print in Antimicrobial Agents and Chemotherapy.

*
In 2023, the U.S. Nontuberculous Mycobacterial (NTM) Infections Treatment Market was valued at approximately USD 360 million and is expected to grow throughout the forecast period (2024-2034).

*
DelveInsight's analysis indicates that among the existing treatments, ARIKAYCE held the largest share of the Nontuberculous Mycobacterial (NTM) Infections Market, generating approximately USD 223 million in revenue for refractory MAC in the U.S. in 2023. This figure is expected to rise throughout the forecast period (2024-2034).

*
In 2023, the Nontuberculous Mycobacterial (NTM) Infections Market in the U.S. saw macrolides account for nearly USD 26 million, while ethambutol and rifamycin/rifampin each contributed approximately USD 16 million to the market share.

*
In 2023, off-label therapies accounted for approximately USD 41 million in the U.S. Nontuberculous Mycobacterial (NTM) Infections Market.

*
Among the 7MM countries, the United States had the highest number of prevalent cases of Nontuberculous Mycobacterial (NTM) infections.

*
Based on DelveInsight's epidemiology model, the total number of diagnosed prevalent cases of Nontuberculous Mycobacterial Infections in the US was around 108,000 in 2023, with an anticipated increase during the forecast period (2024-2034) due to various contributing factors.

*
In 2023, NTM Infections in the US showed a higher prevalence in females compared to males. Females represented about 68% of the total diagnosed prevalent cases of Nontuberculous Mycobacterial Infections, while males accounted for around 32%.

*
In 2023, M. avium had the highest number of diagnosed prevalent cases of Nontuberculous Mycobacterial (NTM) Infections in the U.S., totaling approximately 76,000 cases. This was followed by M. abscessus with around 14,000 cases, while other species (M. kansasii, M. xenopi, etc.) accounted for about 18,000 cases.

*
In the U.S. in 2023, there were around 86,000 diagnosed prevalent cases of pulmonary Nontuberculous Mycobacterial (NTM) Infections and nearly 22,000 cases of the extrapulmonary type.

*
As per Shanmugam et al., about 15 million people died from TB, and nearly 10 million people fall ill with Mtb infection worldwide, of which only 64 million were diagnosed and officially reported

*
Key Non- Tuberculous Mycobacterial Infections Companies: Insmed, AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others

*
Key Non- Tuberculous Mycobacterial Infections Therapies: ARIKAYCE (amikacin liposome inhalation suspension), Epetraborole, MNKD-101 (Clofazimine Inhalation Suspension), SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others

Non- Tuberculous Mycobacterial Infections Overview

Non-Tuberculous Mycobacterial Infections (NTM) are infections caused by mycobacteria species other than Mycobacterium tuberculosis, the bacterium responsible for tuberculosis. These bacteria are commonly found in the environment, such as in soil, water, and dust. NTM infections can affect various parts of the body, including the lungs, skin, and lymph nodes. They are particularly problematic for individuals with weakened immune systems or pre-existing lung conditions, like cystic fibrosis or chronic obstructive pulmonary disease (COPD). Symptoms can include chronic cough, fatigue, weight loss, and shortness of breath, and treatment often involves a combination of antibiotics.

Get a Free sample for the Non- Tuberculous Mycobacterial Infections Market Report:

https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market [https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Non- Tuberculous Mycobacterial Infections Market

The dynamics of the Non- Tuberculous Mycobacterial Infections market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

"Of the Non- Tuberculous Mycobacterial Infections emerging therapies, the most anticipated product to get launched is aminoglycoside antibacterial, Arikayce (amikacin). Apart from this, other products include RHB-204, Thiolanox, Molgradex, and Nitric Oxide. Some of these products have also received Qualified Infectious Disease Product (QIDP), Fastrack Designations and Orphan Designations."

Non- Tuberculous Mycobacterial Infections Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034 It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non- Tuberculous Mycobacterial Infections Epidemiology Segmentation:

The Non- Tuberculous Mycobacterial Infections market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Non- Tuberculous Mycobacterial Infections

*
Prevalent Cases of Non- Tuberculous Mycobacterial Infections by severity

*
Gender-specific Prevalence of Non- Tuberculous Mycobacterial Infections

*
Diagnosed Cases of Episodic and Chronic Non- Tuberculous Mycobacterial Infections

Download the report to understand which factors are driving Non- Tuberculous Mycobacterial Infections epidemiology trends @ Non- Tuberculous Mycobacterial Infections Epidemiological Insights [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Non- Tuberculous Mycobacterial Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non- Tuberculous Mycobacterial Infections market or expected to get launched during the study period. The analysis covers Non- Tuberculous Mycobacterial Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non- Tuberculous Mycobacterial Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non- Tuberculous Mycobacterial Infections Therapies and Key Companies

*
ARIKAYCE (amikacin liposome inhalation suspension): Insmed

*
Epetraborole: AN2 Therapeutics

*
MNKD-101 (Clofazimine Inhalation Suspension): Mannkind Corporation

*
SPR720: Spero Therapeutics

*
Molgramostim: Savara Pharmaceuticals

*
Thiolanox (Nitric Oxide): Mallinckrodt Inc.

*
NUZYRA (omadacycline): Paratek Pharmaceuticals Inc.

*
CYT 107: Revimmune

To know more about Non- Tuberculous Mycobacterial Infections treatment, visit @ Non- Tuberculous Mycobacterial Infections Medications [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Non- Tuberculous Mycobacterial Infections Market Drivers

*
There is increase in spending on branded drugs

*
Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of NTM infections

Non- Tuberculous Mycobacterial Infections Market Unmet Needs

*
Challenges in diagnoses

*
Development of novel therapies

*
Lack of awareness

*
Poor disease understanding

*
Clinical biomarkers

Scope of the Non- Tuberculous Mycobacterial Infections Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Non- Tuberculous Mycobacterial Infections Companies: Insmed, AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others

*
Key Non- Tuberculous Mycobacterial Infections Therapies: ARIKAYCE (amikacin liposome inhalation suspension), Epetraborole, MNKD-101 (Clofazimine Inhalation Suspension), SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others

*
Non- Tuberculous Mycobacterial Infections Therapeutic Assessment: Non- Tuberculous Mycobacterial Infections current marketed and Non- Tuberculous Mycobacterial Infections emerging therapies

*
Non- Tuberculous Mycobacterial Infections Market Dynamics: Non- Tuberculous Mycobacterial Infections market drivers and Non- Tuberculous Mycobacterial Infections market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Non- Tuberculous Mycobacterial Infections Unmet Needs, KOL's views, Analyst's views, Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement

Discover more about therapies set to grab major Non- Tuberculous Mycobacterial Infections market share @ Non- Tuberculous Mycobacterial Infections Treatment Landscape [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Non- Tuberculous Mycobacterial Infections Market Report Introduction

2. Executive Summary for Non- Tuberculous Mycobacterial Infections

3. SWOT analysis of Non- Tuberculous Mycobacterial Infections

4. Non- Tuberculous Mycobacterial Infections Patient Share (%) Overview at a Glance

5. Non- Tuberculous Mycobacterial Infections Market Overview at a Glance

6. Non- Tuberculous Mycobacterial Infections Disease Background and Overview

7. Non- Tuberculous Mycobacterial Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Non- Tuberculous Mycobacterial Infections

9. Non- Tuberculous Mycobacterial Infections Current Treatment and Medical Practices

10. Non- Tuberculous Mycobacterial Infections Unmet Needs

11. Non- Tuberculous Mycobacterial Infections Emerging Therapies

12. Non- Tuberculous Mycobacterial Infections Market Outlook

13. Country-Wise Non- Tuberculous Mycobacterial Infections Market Analysis (2020-2034)

14. Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement of Therapies

15. Non- Tuberculous Mycobacterial Infections Market Drivers

16. Non- Tuberculous Mycobacterial Infections Market Barriers

17. Non- Tuberculous Mycobacterial Infections Appendix

18. Non- Tuberculous Mycobacterial Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=non-tuberculous-mycobacterial-infections-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-insmed-an2-therapeutics-mannkind-corp-spero-therapeutics-savara-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.